Company

Evotec SE

Headquarters: Hamburg, Germany

Employees: 4,081

CEO: Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.

Market Cap

€3.18 Billion

EUR as of Jan. 1, 2024

US$3.51 Billion

Market Cap History

Evotec SE market capitalization over time

Evolution of Evotec SE market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Evotec SE

Detailed Description

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as neuronal diseases, diabetes and complications of diabetes, pain, inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases, and women's health. It has collaboration agreements with Bayer AG; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Celgene; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Top 1-year algo backtest: +284.14%

$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Evotec SE has the following listings and related stock indices.


Stock: FSX: EVT wb_incandescent

Stock: FSX: EVTA wb_incandescent

Stock: XETR: EVTA wb_incandescent

Stock: XETR: EVT wb_incandescent

Stock: OTC: EVOTF wb_incandescent

Stock: OTC: EVTCY wb_incandescent

Details

Headquarters:

Manfred Eigen Campus

Essener Bogen 7

Hamburg, 22419

Germany

Phone: 49 40 5 60 81 0

Fax: 49 40 5 60 81 222